AAM Comments on Section 232 Investigation on Pharmaceuticals
WASHINGTON (April 14, 2025) — The Association for Accessible Medicines today commented on an announcement by the Department of Commerce beginning a Section 232 investigation into possible tariffs and other trade remedies with the goal of encouraging more domestic manufacturing of pharmaceuticals. “AAM and the generics and biosimilars industry look forward to working with the […]
Association for Accessible Medicines Comments on New Tariffs
WASHINGTON (February 2, 2025) — The Association for Accessible Medicines today commented on the announcement that a 25% tariff will be imposed on Canada and Mexico as well as a 10% tariff on China starting today: “The global supply chain for generic and biosimilar medicines is critically important for U.S. patients. From the base ingredients […]
AAM’s Comments on USTR’s Proposed China Tariffs
AAM believes that all finished pharmaceuticals, pharmaceutical ingredients and active pharmaceutical ingredients (API) should be removed from the annex of products to be subject to additional duties published in USTR’s 301 Notice. Imposing an additional 25 percent tariff on such products will increase the cost of prescription drugs for patients in the United States, taxing […]
AAM’s Comments on USTR’s Proposed China Tariffs
WASHINGTON DC (May 14, 2018) – Imposition of tariffs on generic drugs, biosimilars or their ingredients would have a perverse effect on health care spending in the U.S. Generic medicines generated $253 billion in savings for patients and taxpayers in 2016, and in the last decade the U.S. health care system has saved $1.67 trillion […]
AAM Statement on China Tariffs
WASHINGTON, DC (April 4, 2018) – “The Association for Accessible Medicines (AAM) and our members who manufacture generic and biosimilar medicines are aligned with the president’s goal of lowering prescription drug prices for patients in the U.S. We are assessing the proposed tariff list of pharmaceutical ingredients and products by the U.S Trade Representative (USTR) […]
